{"id":"biib122","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BIIB122 blocks LINGO-1 (leucine-rich repeat and Ig domain-containing nogo receptor-interacting protein), which is a negative regulator of oligodendrocyte differentiation and myelin formation. By inhibiting LINGO-1, the drug aims to promote remyelination and restore neurological function in demyelinating diseases. This mechanism is intended to support repair and regeneration of damaged myelin in conditions like multiple sclerosis.","oneSentence":"BIIB122 is a monoclonal antibody that targets and inhibits LINGO-1, a protein that suppresses myelin repair and regeneration in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:21.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (remyelination)"}]},"trialDetails":[{"nctId":"NCT06602193","phase":"PHASE2","title":"Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)","status":"RECRUITING","sponsor":"Denali Therapeutics Inc.","startDate":"2024-10-24","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT05348785","phase":"PHASE2","title":"A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2022-04-19","conditions":"Parkinson Disease","enrollment":650},{"nctId":"NCT06264440","phase":"PHASE1","title":"A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2024-02-12","conditions":"Healthy Volunteer","enrollment":18},{"nctId":"NCT05418673","phase":"PHASE3","title":"A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale","status":"TERMINATED","sponsor":"Biogen","startDate":"2022-08-26","conditions":"Parkinson Disease","enrollment":7},{"nctId":"NCT05229562","phase":"PHASE1","title":"A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2022-02-17","conditions":"Healthy Volunteer","enrollment":84},{"nctId":"NCT05119790","phase":"PHASE1","title":"A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Biogen","startDate":"2021-08-27","conditions":"Healthy Volunteers","enrollment":7},{"nctId":"NCT05005338","phase":"PHASE1","title":"A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects","status":"COMPLETED","sponsor":"Biogen","startDate":"2021-07-28","conditions":"Healthy Volunteers","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DNL151"],"phase":"phase_3","status":"active","brandName":"BIIB122","genericName":"BIIB122","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BIIB122 is a monoclonal antibody that targets and inhibits LINGO-1, a protein that suppresses myelin repair and regeneration in the central nervous system. Used for Multiple sclerosis (remyelination).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}